Piramal Critical Care Docks For China Push
Executive Summary
Peter DeYoung, CEO of Piramal Critical Care
You may also be interested in...
Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Carlyle's 20% Stake Gives Piramal Pharma 'War Chest' For Growth
Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Piramal Pharma Stake Sale On Track
Piramal Enterprises, which is in the process of fundraising for its pharma business, says it is well geared to cater to evolving requirements in the sector amid COVID-19 given its global manufacturing footprint with a strong compliance record. Pharma, the Indian firm’s management maintains, is one of the ‘safest and most resilient’ industries in the current uncertainty.